Company profile
Affymax, Inc.
OTC: AFFY · Healthcare · Biotechnology
#843 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ —GM —SS 33
v0.1 · 5/100 weight · pillars only
↑ listing tenure, Piotroski F · ↓ workforce scale, revenue growth (YoY)
Methodology →Revenue TTM
$42.3k
Rev growth YoY (TTM)
-99.9%
Net income (FY)
-$14.4M
Employees
2
as of 2026-08-28
Market cap
$60.0k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2013
Net income-$14.4M-$14.4M2013
Operating income-$15.0M-$15.0M2013
Total assets$7.4M$7.4M2013
Liabilities$8.9M$8.9M2013
Equity-$1.4M-$1.4M2013
Revenue trend
FY2006 – FY2013 · USD
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY13
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Affymax, Inc.’s revenue?
Affymax, Inc. booked $1.4M in FY2013 revenue, contracting 99% year over year — among the slowest-growing Healthcare companies we track, at a -1053.6% net margin.
Peers · Healthcare
Winston Pharmaceuticals, Inc.——Vasamed, Inc.——Northwest Biotherapeutics, Inc.40DCannaPharmaRX, Inc.38DOneMedNet Corporation26DPanbela Therapeutics, Inc.——Neighbors
New York →Key facts
CEOJonathan Couchman
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeOTC: AFFY
Employees2
IPO date2006-12-15
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.